Verastem, Inc.
NASDAQ:VSTMBiotechnology
Healthcare
$7.41 -0.00%
-$0.00 today
- Market cap
- $933.77M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
52W Low $3.55High $11.25
Volume 2.87M
Average 2.58M
Income Statement
Follow revenue through to earnings.
Revenue
$30.91M
FY 2025 · Annual
+209.1% YoYOperating Income
-$170.13M
FY 2025 · Annual
Net Income
-$209.47M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| 14.53M | 16.14M | 22.05M | 35.71M | 69.31M | |
| 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
VSTM Earnings Waterfall · TTM
NASDAQ:VSTM · Revenue to Net Income
Key Ratios
EPS$-2.73
Gross Margin82.9%
Net Margin-618.4%
P/E Ratio-3.2
P/S Ratio62.6
Analysis
$49.6M of revenue converted into -$194.0M of net income for the selected period. Gross margin is 82.9% and net margin is -618.4%, showing how much revenue survives after costs and taxes. EPS is $-2.73, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| S-8 | S-8 filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
How much revenue does VSTM generate?
Verastem, Inc. (VSTM) reported $30.91M of revenue in fiscal 2025.
Is VSTM profitable?
Verastem, Inc. (VSTM) reported -$209.47M of net income, with a net margin of -677.6%.
Continue the stock analysis
Jump to another research area for this company.